



Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025 (ISIN: BE6325746855)

Liege, Belgium, 25 January 2023 – 17:45 CET - Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "**Company**" or "**Mithra**"), a company dedicated to Women's Health, confirms to Bondholders that, in accordance with the terms and conditions of the Company's EUR 125,000,000 senior unsecured convertible bonds due 2025 (ISIN: BE6325746855) (the "**Bonds**"), as a result of the issuance on 23 November 2023, as part of the private placement announced on 24 August 2023, of (i) 10 million subscription rights, with a 5-year term, to subscribe for 10 million new ordinary shares at an exercise price of EUR 2.25 per share, and (ii) 10 million subscription rights, with a 18-month term, to subscribe for 10 million new ordinary shares at an exercise price of EUR 2.25 per share, pursuant to Condition 5(b), the Conversion Price of the Bonds has been adjusted from EUR 23.2370 to EUR 23.0160, effective as of 23 November 2023.

Capitalised terms not otherwise defined herein shall have the meanings given to them in the terms and conditions of the Bonds.

For more information, please contact:

Mithra Pharmaceuticals SA

Alex Sokolowski, PhD
Head of IR & Communications
investorrelations@mithra.com
+32 (0)4 349 28 22

Frédérique Depraetere
Communications Director
info@mithra.com
+32 (0)4 349 28 22

About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com

ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive press releases by email or follow us on social media:

[Linkedin](#) • [X](#) • [Facebook](#)